Testing cadonilimab plus anlotinib for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have advanced or cannot-be-removed soft tissue sarcoma confirmed by pathology, and the type fits the study list.
- Your cancer got worse after at least one chemotherapy treatment within the last 6 months (for most types).
- You have at least one measurable tumor spot on scan, and your health status score (ECoG) is 0–1.
- Your organs work well enough for treatment (blood counts, kidneys, liver, and clotting tests meet limits).
- You have no major recent treatment issues: no recent immune-based cancer drugs, and your last anti-cancer treatment must be at least 4 weeks ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This Phase 2 trial tests a combination of chemotherapy drugs (Adriamycin and ifosfamide) together with an immunotherapy drug (sintilimab) for advanced soft-tissue sarcoma that can’t be removed by surgery or has stopped responding to standard treatment. It aims to shrink tumors and help control the cancer by boosting the immune system along with chemotherapy.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.